2101 related articles for article (PubMed ID: 23094760)
21. Topiramate for migraine prevention in a naturalistic setting: results from an open label, flexible dose study.
Nelles G; Delbrück A; Schulze L; Kademann B; Bornhoevd K; Schäfer S; Schäuble B;
Headache; 2009; 49(10):1454-65. PubMed ID: 19804392
[TBL] [Abstract][Full Text] [Related]
22. Pharmaceutical care for migraine and headache patients: a community-based, randomized intervention.
Hoffmann W; Herzog B; Mühlig S; Kayser H; Fabian R; Thomsen M; Cramer M; Fiss T; Gresselmeyer D; Janhsen K
Ann Pharmacother; 2008 Dec; 42(12):1804-13. PubMed ID: 19001531
[TBL] [Abstract][Full Text] [Related]
23. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres.
Cevoli S; D'Amico D; Martelletti P; Valguarnera F; Del Bene E; De Simone R; Sarchielli P; Narbone M; Testa L; Genco S; Bussone G; Cortelli P
Cephalalgia; 2009 Dec; 29(12):1285-93. PubMed ID: 19438916
[TBL] [Abstract][Full Text] [Related]
24. Headache prophylaxis with BoNTA: patient characteristics.
Silberstein SD; Marmura MJ; Shaw J; Yu S
Headache; 2010 Jan; 50(1):63-70. PubMed ID: 19549156
[TBL] [Abstract][Full Text] [Related]
25. Headache prevention outcome and body mass index.
Bigal ME; Gironda M; Tepper SJ; Feleppa M; Rapoport AM; Sheftell FD; Lipton RB
Cephalalgia; 2006 Apr; 26(4):445-50. PubMed ID: 16556246
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and patterns of medication use of migraneurs in Latin America from 12 cities in 6 countries.
Morillo LE; Alarcon F; Aranaga N; Aulet S; Chapman E; Conterno L; Estevez E; Garcia-Pedroza F; Garrido J; Macias-Islas M; Monzillo P; Nunez L; Plascencia N; Rodriguez C; Takeuchi Y;
Headache; 2005 Feb; 45(2):118-26. PubMed ID: 15705116
[TBL] [Abstract][Full Text] [Related]
27. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study.
D'Amico D; Solari A; Usai S; Santoro P; Bernardoni P; Frediani F; De Marco R; Massetto N; Bussone G;
Cephalalgia; 2006 Jun; 26(6):691-6. PubMed ID: 16686908
[TBL] [Abstract][Full Text] [Related]
28. Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications.
Cady RK; Voirin J; Farmer K; Browning R; Beach ME; Tarrasch J
Headache; 2012 May; 52(5):749-64. PubMed ID: 22188311
[TBL] [Abstract][Full Text] [Related]
29. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
30. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
[TBL] [Abstract][Full Text] [Related]
31. Predicting disability and quality of life in a community-based sample of women with migraine headache.
Kolotylo CJ; Broome ME
Pain Manag Nurs; 2000 Dec; 1(4):139-51. PubMed ID: 11709867
[TBL] [Abstract][Full Text] [Related]
32. Postmarketing migraine survey of frovatriptan: effectiveness and tolerability vs previous triptans, NSAIDs or a combination.
Cady RK; Banks J; Jones BA; Campbell J
Curr Med Res Opin; 2009 Nov; 25(11):2711-21. PubMed ID: 19778164
[TBL] [Abstract][Full Text] [Related]
33. Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease.
Leonardi M; Raggi A; Pagani M; Carella F; Soliveri P; Albanese A; Romito L
Parkinsonism Relat Disord; 2012 Jan; 18(1):35-9. PubMed ID: 21880537
[TBL] [Abstract][Full Text] [Related]
34. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
Buse D; Manack A; Serrano D; Reed M; Varon S; Turkel C; Lipton R
Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of an intensive multidisciplinary headache treatment program.
Gunreben-Stempfle B; Griessinger N; Lang E; Muehlhans B; Sittl R; Ulrich K
Headache; 2009 Jul; 49(7):990-1000. PubMed ID: 19473281
[TBL] [Abstract][Full Text] [Related]
36. The Migraine Intervention Score - a tool to improve efficacy of triptans in acute migraine therapy: the ALADIN study.
Göbel H; Heinze A
Int J Clin Pract; 2011 Aug; 65(8):879-86. PubMed ID: 21762313
[TBL] [Abstract][Full Text] [Related]
37. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.
Bigal ME; Rapoport AM; Sheftell FD; Tepper SJ; Lipton RB
Cephalalgia; 2004 Jun; 24(6):483-90. PubMed ID: 15154858
[TBL] [Abstract][Full Text] [Related]
38. Occipital nerve stimulation for chronic migraine: a randomized trial.
Serra G; Marchioretto F
Pain Physician; 2012; 15(3):245-53. PubMed ID: 22622909
[TBL] [Abstract][Full Text] [Related]
39. A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.
Landy SH; Turner IM; Runken MC; Lee M; Sulcs E; Bell CF
Headache; 2013; 53(7):1134-46. PubMed ID: 23773016
[TBL] [Abstract][Full Text] [Related]
40. Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: a case series.
Novack V; Fuchs L; Lantsberg L; Kama S; Lahoud U; Horev A; Loewenthal N; Ifergane G
Cephalalgia; 2011 Oct; 31(13):1336-42. PubMed ID: 21700645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
